See more : AAA Technologies Limited (AAATECH.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Hikma Pharmaceuticals PLC (HKMPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hikma Pharmaceuticals PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Ruixin International Holdings Limited (0724.HK) Income Statement Analysis – Financial Results
- Meitav DASH Investments Ltd (MTDS.TA) Income Statement Analysis – Financial Results
- Silverlake Axis Ltd (5CP.SI) Income Statement Analysis – Financial Results
- Hota Industrial Mfg. Co., Ltd. (1536.TW) Income Statement Analysis – Financial Results
- Thai Oil Public Company Limited (TOP-R.BK) Income Statement Analysis – Financial Results
Hikma Pharmaceuticals PLC (HKMPF)
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.88B | 2.52B | 2.55B | 2.34B | 2.21B | 2.07B | 1.94B | 1.95B | 1.44B | 1.49B | 1.37B | 1.11B | 918.03M | 730.94M | 636.88M | 580.66M | 448.80M | 317.02M | 262.22M | 212.38M | 105.15M | 85.50M |
| Cost of Revenue | 1.47B | 1.28B | 1.25B | 1.14B | 1.06B | 1.02B | 969.00M | 964.00M | 622.00M | 638.00M | 601.00M | 607.60M | 522.68M | 373.59M | 332.46M | 324.17M | 227.26M | 158.49M | 126.42M | 103.94M | 51.57M | 40.58M |
| Gross Profit | 1.41B | 1.24B | 1.30B | 1.20B | 1.15B | 1.05B | 967.00M | 986.00M | 818.00M | 851.00M | 764.00M | 501.12M | 395.35M | 357.34M | 304.43M | 256.48M | 221.53M | 158.53M | 135.79M | 108.44M | 53.58M | 44.92M |
| Gross Profit Ratio | 48.94% | 49.19% | 50.96% | 51.30% | 52.02% | 50.72% | 49.95% | 50.56% | 56.81% | 57.15% | 55.97% | 45.20% | 43.07% | 48.89% | 47.80% | 44.17% | 49.36% | 50.01% | 51.79% | 51.06% | 50.96% | 52.54% |
| Research & Development | 149.00M | 144.00M | 143.00M | 137.00M | 150.00M | 147.00M | 115.00M | 150.00M | 36.00M | 55.00M | 39.00M | 34.02M | 31.22M | 23.61M | 16.84M | 22.17M | 19.34M | 18.29M | 16.51M | 9.67M | 4.13M | 3.01M |
| General & Administrative | 638.00M | 509.00M | 488.00M | 464.00M | 453.00M | 246.00M | 238.00M | 208.00M | 180.00M | 185.00M | 151.00M | 124.56M | -43.12M | -29.85M | -38.86M | -47.35M | -17.67M | -4.96M | -4.76M | -4.63M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 494.00M | 224.00M | 188.00M | 184.00M | 156.00M | 171.00M | 160.00M | 152.76M | 125.30M | 106.67M | 98.08M | 90.56M | 61.02M | 35.01M | 27.37M | 19.73M | 0.00 | 0.00 |
| SG&A | 638.00M | 509.00M | 488.00M | 464.00M | 494.00M | 470.00M | 426.00M | 392.00M | 336.00M | 356.00M | 311.00M | 277.32M | 82.17M | 76.83M | 59.23M | 43.21M | 43.35M | 30.05M | 22.61M | 15.10M | 0.00 | 0.00 |
| Other Expenses | 253.00M | 0.00 | 0.00 | 0.00 | -50.88M | -59.22M | -60.92M | -88.83M | -54.02M | 0.00 | 0.00 | -1.17M | 2.33M | 0.00 | 0.00 | 0.00 | 0.00 | 938.00K | 1.45M | 732.00K | 0.00 | 0.00 |
| Operating Expenses | 1.04B | 756.00M | 742.00M | 687.00M | 655.00M | 690.00M | 635.00M | 611.00M | 401.00M | 449.00M | 412.00M | 334.34M | 276.73M | 222.04M | 197.80M | 176.64M | 129.34M | 84.16M | 67.59M | 46.06M | 22.62M | 20.29M |
| Cost & Expenses | 2.51B | 2.04B | 1.99B | 1.83B | 1.71B | 1.71B | 1.60B | 1.58B | 1.02B | 1.09B | 1.01B | 941.95M | 799.41M | 595.63M | 530.26M | 500.81M | 356.60M | 242.65M | 194.02M | 150.00M | 74.19M | 60.87M |
| Interest Income | 7.00M | 3.00M | 30.00M | 47.00M | 67.00M | 3.00M | 2.00M | 12.00M | 3.00M | 4.00M | 2.00M | 1.27M | 468.00K | 346.00K | 514.00K | 817.00K | 2.03M | 5.26M | 1.56M | 326.00K | 290.00K | 117.00K |
| Interest Expense | 90.00M | 77.00M | 69.00M | 69.00M | 67.00M | 80.00M | 60.00M | 104.00M | 57.00M | 38.00M | 37.00M | 35.72M | 23.37M | 13.86M | 12.83M | 17.55M | 10.84M | 4.96M | 5.21M | 3.83M | 1.90M | 2.55M |
| Depreciation & Amortization | 195.60M | 186.55M | 164.15M | 143.91M | 121.49M | 104.11M | 142.86M | 102.57M | 73.00M | 72.00M | 75.00M | 58.39M | 47.00M | 38.43M | 34.15M | 33.12M | 23.43M | 13.80M | 10.33M | 6.77M | 3.06M | 4.89M |
| EBITDA | 572.47M | 485.00M | 735.00M | 796.28M | 685.36M | 435.55M | -570.38M | 350.74M | 484.00M | 472.00M | 426.00M | 226.15M | 164.19M | 165.38M | 141.10M | 114.47M | 117.32M | 94.35M | 79.70M | 70.01M | 34.64M | 28.71M |
| EBITDA Ratio | 19.91% | 27.81% | 28.79% | 27.85% | 29.86% | 23.38% | 81.35% | 27.33% | 33.61% | 31.70% | 31.21% | 20.40% | 17.89% | 23.73% | 22.15% | 19.61% | 26.26% | 29.78% | 31.20% | 32.97% | 32.91% | 33.58% |
| Operating Income | 367.00M | 282.00M | 582.00M | 579.00M | 493.00M | 371.00M | -747.00M | 302.00M | 381.00M | 402.00M | 352.00M | 166.77M | 118.69M | 135.10M | 107.29M | 80.68M | 92.40M | 75.25M | 69.21M | 62.72M | 30.99M | 22.46M |
| Operating Income Ratio | 12.77% | 11.20% | 22.80% | 24.73% | 22.34% | 17.92% | -38.58% | 15.49% | 26.46% | 27.00% | 25.79% | 15.04% | 12.93% | 18.48% | 16.85% | 13.89% | 20.59% | 23.74% | 26.39% | 29.53% | 29.47% | 26.27% |
| Total Other Income/Expenses | -86.00M | -49.00M | -38.00M | -21.00M | -2.00M | -78.00M | 9.00M | -92.00M | -63.00M | -40.00M | -54.00M | -35.00M | -24.80M | -14.11M | -12.51M | -16.65M | -8.61M | 348.60K | -4.80M | -3.70M | -1.32M | -3.37M |
| Income Before Tax | 281.00M | 233.00M | 544.00M | 558.00M | 491.00M | 293.00M | -738.00M | 210.00M | 318.00M | 362.00M | 298.00M | 132.04M | 93.89M | 120.98M | 94.79M | 64.03M | 83.79M | 75.60M | 64.41M | 59.02M | 29.67M | 19.10M |
| Income Before Tax Ratio | 9.77% | 9.26% | 21.31% | 23.84% | 22.25% | 14.15% | -38.12% | 10.77% | 22.08% | 24.31% | 21.83% | 11.91% | 10.23% | 16.55% | 14.88% | 11.03% | 18.67% | 23.85% | 24.56% | 27.79% | 28.22% | 22.33% |
| Income Tax Expense | 89.00M | 42.00M | 124.00M | 128.00M | 4.00M | 8.00M | 101.00M | 52.00M | 64.00M | 80.00M | 82.00M | 24.83M | 10.42M | 21.46M | 15.47M | 6.92M | 19.60M | 19.64M | 19.45M | 20.84M | 11.91M | 8.52M |
| Net Income | 190.00M | 188.00M | 421.00M | 431.00M | 486.00M | 282.00M | -843.00M | 155.00M | 252.00M | 278.00M | 212.00M | 100.00M | 80.11M | 98.85M | 77.68M | 57.12M | 62.58M | 54.52M | 43.87M | 37.46M | 17.59M | 10.50M |
| Net Income Ratio | 6.61% | 7.47% | 16.49% | 18.41% | 22.02% | 13.62% | -43.54% | 7.95% | 17.50% | 18.67% | 15.53% | 9.02% | 8.73% | 13.52% | 12.20% | 9.84% | 13.94% | 17.20% | 16.73% | 17.64% | 16.73% | 12.28% |
| EPS | 0.86 | 0.82 | 1.79 | 1.95 | 2.09 | 1.17 | -3.51 | 0.67 | 1.27 | 1.40 | 1.08 | 0.51 | 0.41 | 0.51 | 0.41 | 0.30 | 0.37 | 0.33 | 0.30 | 26.30 | 0.11 | 0.06 |
| EPS Diluted | 0.85 | 0.82 | 1.78 | 1.93 | 2.08 | 1.17 | -3.50 | 0.66 | 1.25 | 1.39 | 1.07 | 0.51 | 0.41 | 0.50 | 0.40 | 0.30 | 0.35 | 0.31 | 0.28 | 24.80 | 0.11 | 0.06 |
| Weighted Avg Shares Out | 220.86M | 224.00M | 231.00M | 236.00M | 242.00M | 241.00M | 240.00M | 233.00M | 199.00M | 198.00M | 197.00M | 196.35M | 194.14M | 192.30M | 189.76M | 187.88M | 169.22M | 167.28M | 154.86M | 166.54M | 166.54M | 166.54M |
| Weighted Avg Shares Out (Dil) | 222.37M | 225.00M | 233.00M | 238.00M | 243.00M | 242.00M | 241.00M | 234.00M | 201.00M | 200.00M | 198.00M | 198.30M | 197.77M | 196.86M | 193.73M | 193.17M | 176.85M | 175.92M | 154.86M | 166.54M | 166.54M | 166.54M |
U.K. Dividend Stocks Portfolio: 2023 Year-End Review
U.K. Dividend Stocks Portfolio: 2023 Year-End Review
Hikma Pharmaceuticals upgrades guidance for all segments except injectables
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has upgraded its full-year guidance for two out of three of its business segments following “good momentum” in the first half, but lowered annual sales expectations for injectables, it said in a trading update today. ...
Selling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 Months
Hikma Pharmaceuticals is a FTSE 250 generic drug manufacturer that was founded in the Middle East in 1978. The company has many attractive features, including a long track record of progressive dividend growth, so I added it to my dividend...
Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Call Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 AM ET Company Participants Susan Ringdal - EVP, Strategic Planning and Global Affairs Said Darwazah - Chief Executive Officer Brian Hoffmann - President of Generics Riad Mishlawi...
Hikma Pharmaceuticals higher as Citi analysts revise target price
Analysts at Citi have revised their net present value (NPV)-based price target for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to £19.20 with a £28-£11 bull-bear valuation range for the stock. In a note to clients, the analysts said: "Our Deconstructed-Buy-Thesis back in August...
Hikma Pharmaceuticals launches generic version of narcolepsy treatment Xyrem in US
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) said it has launched an authorised generic version of Jazz Pharmaceuticals' Xyrem (sodium oxybate) oral solution CIII. Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat people with narcolepsy for symptoms of...
Hikma Pharmaceuticals Plc (HKMPF) 2022 Interim Results - Earnings Call Transcript
Hikma Pharmaceuticals Plc. (OTCPK:HKMPF) 2022 Interim Results August 4, 2022 5:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference Call Participants Said Darwazah Hello everyone.
Hikma Pharmaceuticals loses CEO
The chief executive of Hikma Pharmaceuticals PLC (AIM:HIK, OTC:HKMPF), Siggi Olafsson, has stepped down from the role, with a permanent replacement yet to be found. The British injectable medicine business announced today that Olafsson had resigned from the post and...
Hikma Pharmaceuticals PLC (HKMPF) CEO Sigurdur Olafsson on Q4 2021 Results - Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) CEO Sigurdur Olafsson on Q4 2021 Results - Earnings Call Transcript
Hikma Pharmaceuticals sales grow 9%, announces US$300mln share buyback
Hikma Pharmaceuticals PLC (AIM:HIK, OTC:HKMPF) reported “solid growth” for 2021, with sales rising 9% on the back of a good performance in all its three businesses. The multinational pharmaceutical company also announced plans to return US$300mln to shareholders via a...
Source: https://incomestatements.info
Category: Stock Reports